These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Insights into thrombin activatable fibrinolysis inhibitor function and regulation. Foley JH; Kim PY; Mutch NJ; Gils A J Thromb Haemost; 2013 Jun; 11 Suppl 1():306-15. PubMed ID: 23809134 [TBL] [Abstract][Full Text] [Related]
10. Characterization of thrombin activatable fibrinolysis inhibitor in normal and acquired haemostatic dysfunction. Toh CH Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S69-71. PubMed ID: 14567541 [TBL] [Abstract][Full Text] [Related]
11. A role for arginine-12 in thrombin-thrombomodulin-mediated activation of thrombin-activatable fibrinolysis inhibitor. Plug T; Kramer G; Meijers JC J Thromb Haemost; 2014 Oct; 12(10):1717-25. PubMed ID: 25066897 [TBL] [Abstract][Full Text] [Related]
12. Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential. Marar TT; Boffa MB Res Pract Thromb Haemost; 2024 May; 8(4):102459. PubMed ID: 38983903 [TBL] [Abstract][Full Text] [Related]
13. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin. Mosnier LO J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299 [TBL] [Abstract][Full Text] [Related]
14. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and regulation of fibrinolysis. Mosnier LO; Meijers JC; Bouma BN Thromb Haemost; 2001 Oct; 86(4):1040-6. PubMed ID: 11686322 [TBL] [Abstract][Full Text] [Related]
15. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms. Mishra N; Vercauteren E; Develter J; Bammens R; Declerck PJ; Gils A Thromb Haemost; 2011 Jul; 106(1):90-101. PubMed ID: 21544309 [TBL] [Abstract][Full Text] [Related]
16. Thrombin activatable fibrinolysis inhibitor (TAFI): a molecular link between coagulation and fibrinolysis. Miljić P; Heylen E; Willemse J; Djordjević V; Radojković D; Colović M; Elezović I; Hendriks D Srp Arh Celok Lek; 2010 Jan; 138 Suppl 1():74-8. PubMed ID: 20229688 [TBL] [Abstract][Full Text] [Related]
17. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation. Incampo F; Carrieri C; Semeraro N; Colucci M Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406 [TBL] [Abstract][Full Text] [Related]
18. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis]. Stasko J; Hudecek J; Kubisz P Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228 [TBL] [Abstract][Full Text] [Related]
19. [Regulatory mechanism of fibrinolysis system by thrombin activatable fibrinolysis inhibitor (TAFI)]. Urano T Nihon Yakurigaku Zasshi; 2000 Nov; 116(5):298-303. PubMed ID: 11215380 [TBL] [Abstract][Full Text] [Related]
20. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation. Zhou X; Declerck PJ J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]